statistiche ricercatore

CANDUCCI, FILIPPO

Distribuzione geografica

Continente	#
NA - Nord America	6.917
EU - Europa	3.106
AS - Asia	1.895
SA - Sud America	129
Continente sconosciuto - Info sul continente non disponibili	34
AF - Africa	21
OC - Oceania	4
Totale	12.106

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	6.729
IT - Italia	1.708
SG - Singapore	623
UA - Ucraina	504
VN - Vietnam	327
TR - Turchia	317
CN - Cina	308
SE - Svezia	249
HK - Hong Kong	217
FI - Finlandia	134
CA - Canada	128
DE - Germania	115
BR - Brasile	101
FR - Francia	98
IE - Irlanda	93
GB - Regno Unito	91
RU - Federazione Russa	62
JP - Giappone	24
IN - India	23
MX - Messico	21
BD - Bangladesh	12
AR - Argentina	11
ES - Italia	10
NL - Olanda	10
BE - Belgio	9
EU - Europa	9
IQ - Iraq	9
PL - Polonia	8
ZA - Sudafrica	8
CR - Costa Rica	7
EC - Ecuador	6
ID - Indonesia	6
NI - Nicaragua	6
TT - Trinidad e Tobago	6
AT - Austria	5
GT - Guatemala	5
LT - Lituania	4
VE - Venezuela	4
CL - Cile	3
CW - ???statistics.table.value.countryCode.CW???	3
EG - Egitto	3
HN - Honduras	3
IL - Israele	3
KE - Kenya	3
AE - Emirati Arabi Uniti	2
AU - Australia	2
BZ - Belize	2
DO - Repubblica Dominicana	2
DZ - Algeria	2
ET - Etiopia	2
JM - Giamaica	2
KZ - Kazakistan	2
LB - Libano	2
MD - Moldavia	2
MY - Malesia	2
NG - Nigeria	2
NP - Nepal	2
NZ - Nuova Zelanda	2
PE - Perù	2
PH - Filippine	2
PK - Pakistan	2
PR - Porto Rico	2
SA - Arabia Saudita	2
BB - Barbados	1
BH - Bahrain	1
BS - Bahamas	1
BY - Bielorussia	1
CZ - Repubblica Ceca	1
EE - Estonia	1
GD - Grenada	1
GP - Guadalupe	1
GY - Guiana	1
JO - Giordania	1
KG - Kirghizistan	1
KR - Corea	1
KW - Kuwait	1
MA - Marocco	1
NO - Norvegia	1
OM - Oman	1
PS - Palestinian Territory	1
SX - ???statistics.table.value.countryCode.SX???	1
SY - Repubblica araba siriana	1
TH - Thailandia	1
UY - Uruguay	1
UZ - Uzbekistan	1
Totale	12.085

Salva come PNG Salva come JPEG

Città	#
Milan	1.283
Fairfield	841
Ashburn	544
Woodbridge	508
San Jose	478
Jacksonville	430
Houston	388
Singapore	365
Chandler	350
Ann Arbor	313
Seattle	302
Cambridge	298
Wilmington	275
Hong Kong	213
Council Bluffs	174
Nyköping	163
Princeton	144
Izmir	141
Dallas	137
Dearborn	137
Boardman	115
The Dalles	110
Toronto	99
Dong Ket	93
Dublin	89
Beijing	84
Rome	76
Lauterbourg	62
Como	54
Hanoi	46
San Diego	46
Ho Chi Minh City	41
Santa Clara	32
Los Angeles	28
New York	28
Tokyo	23
Chicago	22
London	21
Nanjing	20
Ogden	20
Kunming	16
Orem	16
Atlanta	15
Hefei	15
São Paulo	15
Mexico City	14
Denver	11
Haiphong	11
Phoenix	11
Washington	11
Da Nang	10
Montreal	10
Brooklyn	9
Brussels	9
Munich	9
Verona	9
Chengdu	8
Chennai	8
Columbus	8
Guangzhou	8
Warsaw	8
Helsinki	7
Jinan	7
Mumbai	7
Norwalk	7
Nuremberg	7
Salt Lake City	7
Nanchang	6
Ponte Lambro	6
San José	6
Baghdad	5
Guatemala City	5
Hounslow	5
Johannesburg	5
Managua	5
Poplar	5
Boston	4
Charlotte	4
Greater Sudbury	4
Guayaquil	4
Kilburn	4
Las Vegas	4
Miami	4
Palermo	4
Redmond	4
San Francisco	4
Wuhan	4
Alexandria	3
Amsterdam	3
Can Tho	3
Curitiba	3
Elk Grove Village	3
Fuzhou	3
Harrisburg	3
Huzhou	3
Milwaukee	3
Nairobi	3
North Bergen	3
Phú Nhuận	3
Pittsburgh	3
Totale	8.997

Salva come PNG Salva come JPEG

Nome	#
Duodenal mucosa of patients with type 1 diabetes shows distinctive inflammatory profile and microbiota	234
The Microbiome of the Prostate Tumor Microenvironment	226
Kuwanon-L as a New Allosteric HIV-1 Integrase Inhibitor: Molecular Modeling and Biological Evaluation	225
Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients.	216
Adaptive immunity against gut microbiota enhances apoE-mediated immune regulation and reduces atherosclerosis and western-diet-related inflammation	215
One drug for two targets: Biological evaluation of antiretroviral agents endowed with antiproliferative activity	212
Cross-reacting antibacterial auto-antibodies are produced within coronary atherosclerotic plaques of acute coronary syndrome patients.	209
Inhibition of HIV-1 Reverse Transcriptase Dimerization by Small Molecules	206
Coronaviridae and SARS-associated coronavirus strain HSR1.	204
Antigen-driven evolution of B lymphocytes in coronary atherosclerotic plaques.	204
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates.	196
The interplay of extracellular matrix and microbiome in urothelial bladder cancer	193
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study.	192
Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site.	189
Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.	187
Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection.	187
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL-authors' response	184
Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up	182
Efficacy of a multistep strategy for Helicobacter pylori eradication.	182
Immunological recovery after 24 weeks of antiretroviral therapy in patients with x4 virus during primary hiv infection	182
Natural Product Kuwanon-L Inhibits HIV-1 Replication through Multiple Target Binding	182
Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy.	182
Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV).	180
Helicobacter pylori treatment: a role for probiotics?	179
2-aminothiazolones as anti-HIV agents which act as gp120-CD4 Inhibitors	178
Integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-1 infection.	177
Epidemiological, molecular and clinical features of enterovirus 109 infection in children and in adult stem cell transplant recipients.	176
Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.	173
Cloning and molecular characterization of a human recombinant IgG Fab binding to the Tat protein of human immunodeficiency virus type 1 (HIV-1) derived from the repertoire of a seronegative patient.	172
Oral probiotic VSL#3 prevents autoimmune diabetes by modulating microbiota and promoting indoleamine 2,3-dioxygenase-enriched tolerogenic intestinal environment	172
Quantitation of Bacillus clausii in biological samples by real-time polymerase chain reaction.	170
Onset of Berger disease after Staphylococcus aureus infection: septic arthritis after anterior cruciate ligament reconstruction.	170
GB virus C and survival in persons with HIV infection	168
Revealing enterovirus infection in chronic human disorders: An integrated diagnostic approach	168
Probiotics and Helicobacter pylori eradication.	166
HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients.	166
Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression	166
Two-year prospective study of single infections and co-infections by respiratory syncytial virus and viruses identified recently in infants with acute respiratory disease.	165
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.	164
Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects.	164
IL28B rs12979860 genotype as a predictor marker of progression to BKVirus Associated nephropathy, after kidney transplantation	162
Persistent replication of severe acute respiratory syndrome coronavirus in human tubular kidney cells selects for adaptive mutations in the membrane protein.	162
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL.	161
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.	161
Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family	161
Comparison of the artus HIV-1 QS-RGQ and VERSANT HIV-1 RNA 1.0 assays for quantitative detection of human immunodeficiency virus type 1 in plasma samples	161
Pregnancy and H1N1 infection.	159
In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir	159
The role of infections and coinfections with newly identified and emerging respiratory viruses in children.	159
Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients.	158
Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure.	158
Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts.	158
Molecular epidemiology of KI and WU polyomaviruses in infants with acute respiratory disease and in adult hematopoietic stem cell transplant recipients.	157
Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.	155
Characterization of GBV-C infection in HIV-1 infected patients.	154
Infection and coinfection of human rhinovirus C in stem cell transplant recipients.	153
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy.	153
Rifabutin-based Helicobacter pylori eradication 'rescue therapy'.	152
A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments.	151
The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir.	144
Quantitative HIV-1 proviral DNA detection: a multicentre analysis.	137
Heterogeneity of the humoral anti-HCV/E2 response in persistently infected patients as demonstrated by divergent patterns of inhibition of the binding of anti-HCV/E2 human monoclonal antibodies.	132
Phage display for the production of human monoclonal antibodies against human pathogens.	126
Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV).	121
Humoral immune response against hepatitis C virus.	119
Targeting patients' microbiota with probiotics and natural fibers in adults and children with constipation	119
Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.	115
Helicobacter pylori: a culprit in extraintestinal diseases?	113
Long-term study on symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients.	108
Phylogenetic internal control for HIV-1 genotypic antiretroviral testing.	107
Intra-host evolution of human immunodeficiency virus type 1 and viral fitness.	105
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group.	102
TMEM219 signaling promotes intestinal stem cell death and exacerbates colitis	101
Totale	12.106

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	47.695
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	47.695

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	428	0	0	0	53	8	21	41	42	33	82	66	82
2022/2023	990	79	6	48	114	111	245	1	135	184	26	14	27
2023/2024	1.794	311	330	304	338	353	83	5	13	36	4	0	17
2024/2025	701	1	1	151	5	6	77	65	18	25	54	64	234
2025/2026	2.139	187	133	96	248	211	109	446	117	299	157	101	35
2026/2027	693	42	106	330	215	0	0	0	0	0	0	0	0
Totale													12.106